Catalog | Name | Composition | Particle size | Specifications | Storage condition | Shelf life | Application | Description |
NZs-58 | Red emissive carbon dots | Carbon dots | 3-5 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Bioimaging and ameliorating acute lung injury | Red emissive carbon dots have SOD-like activity up to 4000 U·mg−1. They can effectively enter cells, remove harmful reactive oxygen species (ROS), and protect cells from oxidative damage. |
NZs-59 | HA/Pt/Qu nanogel | Hyaluronic acid (HA), Pt nanoparticles (Pt NPs), quinacrine (Qu) | 5-10 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Fluorescence imaging of lysosomes | HA/Pt/Qu nanogel can remove ROS generated by light excitation in situ through the SOD-like properties of Pt NPs, thereby reducing phototoxicity, maintaining the integrity of the lysosome structure and further achieving efficient and low-toxic live cell fluorescence imaging. |
NZs-60 | CeVO4 nanozymes | CeVO4 | 50-150 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Regulating neuronal cell mitochondrial function | Cerium vanadate nanozyme can catalyze the conversion of superoxide into hydrogen peroxide and oxygen under physiological conditions. So cerium vanadate nanozyme can prevent the mitochondrial damage in cytosolic SOD and mitochondrial SOD-depleted cells by regulating the superoxide levels, thereby restoring the mitochondrial function and regulating the ATP levels. |
NZs-61 | MnPS3 | MnPS3 | length of about 1 μm, width of about 200 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Androgenetic alopecia treatment | The IC50 of MnPS3 is 3.61 μg·ml-1, up to 12-fold lower than most reported SOD-like nanozymes. Moreover, a MnPS3 microneedle patch can be used to treat androgenetic alopecia that could diffuse into the deep skin where hair follicles exist and remove excess ROS. |
NZs-62 | Gly-Cu(OH)2 NPs | Glycine, Cu(OH)2 | about 200 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Embedded in cigarette filters to remove ROS from smoke | Gly-Cu(OH)2 nanoparticles (NPs) are readily dispersible in aqueous media and can catalyze the decomposition of superoxide. Due to their extraordinarily high SOD activity, Gly-Cu(OH)2 NPs incorporate in cigarette filters efficiently removed toxic ROS radicals from cigarette smoke. |
NZs-63 | NiO nanoflowers | NiO | 2-5 μm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Antioxidants for fighting ROS-related diseases | NiO nanoflowers (NFs) could catalytically scavenge O2•- into O2 and H2O2, exhibiting intrinsic SOD-like activity. NiO NFs have appropriate redox potential and can cycle between the NiII and NiIII oxidation states, thereby displaying the SOD-like activity. |
NZs-64 | Mn-doped ZnS QDs | Mn, ZnS | 30 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | —— | Mn-doped ZnS quantum dots (QDs) exhibit intrinsic SOD-like activity. They have low cost, good biocompatibility, and are easy to synthesize. Mn-doped ZnS QDs are expected to be used as a new type of SOD nanozymes in the biology-relevant fields. |
NZs-65 | PZIF67-AT | Zeolitic imidazole framework (ZIF)-67, polyethylene glycol (PEG), 3-amino-1,2,4-
triazole (3-AT) | 100-200 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Intensify chemodynamic therapy (CDT) | PZIF67-AT is a nanozyme-based H2O2 homeostasis disruptor. With highly SOD-like activity, inhibiting catalase (CAT) activity, and depleting glutathione (GSH) ability, the disruptor could interfere with H2O2 homeostasis through accelerating the production and restrain the elimination of H2O2, leading to the elevation of the H2O2 level in cancer cells. |
NZs-66 | Cu-TCPP MOF nanodots | Cu-Tris(chlorisopro-pyl)Phosphate (TCPP) | 50 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Alleviating endotoxemia | Cu-TCPP MOF nanodots have biomimetic size, the similar metal active sites coordination environment to natural SOD and the ordered channels akin to the substrate channels, exhibiting efficient SOD-like activity and can be used to alleviate endotoxemia. They also possess glutathione peroxidases (GPx)-like activity, which could be used as a powerful enzymecooperative platform to defend cell components from severe oxidative stress. |
NZs-7 | 2D cobalt hydroxide oxide
nanosheets | Co | 50-70 nm | 50 mg
100 mg | -4 ℃, -20 ℃ | 6 months in sealed condition | Inhibit inflammation | 2D cobalt hydroxide oxide nanosheets exhibit superior reactive oxygen species (ROS) scavenging properties and can protect cells from oxidative damage. |
NZs-25 | Prussian blue nanozymes | Fe4[Fe(CN)6]3, KFe[Fe(CN)6] | about 200 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Antioxidant and anti-inflammatory materials, etc. | Prussian blue nanozymes can effectively scavenge ROS via multi-enzyme activities including peroxidase (POD)-like activity, CAT-like activity and SOD-like activity. Prussian blue nanozymes can be used as new antioxidant and anti-inflammatory materials, and can also be used in the fields such as drug loading, photothermal therapy, inflammatory tissue imaging and construction of biosensor devices. |
NZs-26 | Fe3O4 nanozymes | Fe3O4 | 200 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Promote stroke
healing | Fe3O4 nanozymes exhibit triple enzyme-like activities including POD, CAT, and SOD, thus potentially possessing the ability to regulate the ROS level. |
NZs-27 | SiO2@MPGs | SiO2 nanoparticles, metal coordinated polymeric nanogels (MPGs) | —— | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Bioresponsive fluorescence imaging | SiO2@MPGs exhibit POD and SOD activities. Their thermal stability is better than molecular enzyme mimics and natural horseradish peroxidase (HRP). |
NZs-40 | RuO2 NPs | RuO2 | 5 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Prevention of acute kidney injury | RuO2 NPs catalytic properties mimic the activity of SOD, POD, CAT and GPx. In addition, RuO2 NPs show excellent antioxidant activity and low biological toxicity. And the nanozyme can be efficiently and rapidly absorbed by human embryonic kidney cells while significantly reducing ROS-induced apoptosis by eliminating excess ROS. |
NZs-52 | V2O5@pDA@MnO2 | V2O5, polydopamine (pDA), MnO2 | about 200 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Inflammation therapy | V2O5@pDA@MnO2 nanocomposite could serve as one multi-nanozyme model to mimic intracellular antioxidant defense procedure in which SOD, CAT, GPx, etc. It exhibited excellent intracellular ROS removal ability to protect the body against oxidative stress, showing its potential application in inflammation therapy. |
NZs-53 | Mn3O4 nanozyme | Mn3O4 | 500 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Prevent
ROS-mediated neurological disorders. | Mn3O4 nanozyme functionally mimic three major antioxidant enzymes, namely SOD, CAT and GPx, and the multienzyme activity is size as well as morphologydependent. It can robustly rescue the cells from oxidative damage and thereby possess therapeutic potential to prevent ROS-mediated neurological disorders. |
NZs-54 | MOF-818 | MOF-818 | 200-400 nm | 50 mg
100 mg | -4 ℃ | 6 months in sealed condition | Chronic wound treatment | MOF-818 have high SOD and CAT activities, which can scavenge ROS at wound sites. In addition, they also have good biocompatibility. |
NZs-56 | Cu5.4O USNPs | Cu5.4O | 200-400 nm | 50 mg
500 mg | -4 ℃ | 6 months in sealed condition | Treatment of ROS-related diseases | Ultrasmall copper based nanoparticles (Cu5.4O USNPs) have the distinctive advantages of the ultrasmall particle size, rapid renal clearance, high biocompatibility and broad reactive oxygen species (ROS) scavenging abilities. Cu5.4O USNPs simultaneously possessing SOD-, CAT- and GPx-mimicking enzyme properties exhibit cytoprotective effects against ROS-mediated damage at extremely low dosage and significantly improve treatment outcomes in acute kidney injury, acute liver injury and wound healing. Meanwhile, the ultrasmall size of Cu5.4O USNPs enables rapid renal clearance of the nanomaterial, guaranteeing the biocompatibility. The protective effect and good biocompatibility of Cu5.4O USNPs will facilitate clinical treatment of ROS-related diseases and enable the development of next-generation nanozymes. |